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Proper protein folding is essential for normal immunoglobulin synthesis and secretion in anti bodysecreting plasma cells (PCs). The mam malian unfolded protein response (UPR) is a signaling pathway that responds to ER stress that is induced by the accumulation of unfolded proteins within the ER lumen (Todd et al., 2008) . Inositolrequiring transmembrane ki nase/endonuclease 1 (IRE1) is an ERlocalized transmembrane protein that senses unfolded proteins and serves to activate Xbox binding protein 1 (XBP1), a member of the CREB/ ATF basic leucine zipper family of transcription factors and a crucial mediator of one branch of the UPR (Yoshida et al., 2001; Calfon et al., 2002; Lee et al., 2002) . IRE1 possesses endo ribonuclease activity that excises a 26nt sequence from XBP1 messenger RNA (mRNA). This event, termed XBP1 splicing, shifts the reading frame to excise a premature stop codon, resulting in a fulllength functional XBP1 protein prod uct (Yoshida et al., 2001; Calfon et al., 2002; Lee et al., 2002) . XBP1 then translocates to the nucleus where it induces target genes involved in protein synthesis and secretion (Shaffer et al., 2004; Lee et al., 2005) .
XBP1 activation is crucial to the normal function and survival of highly secretory cells such as exocrine gland acinar cells and Paneth cells (Kaser et al., 2008) . Using XBP1/RAG2 / lymphoid chimeric mice, we have shown in cell surface expression of IgM and IgD between XBP1 CD19 and XBP1 +/+ splenocytes (Fig. S1 B) . In accord with the known function of XBP1 in PC development, basal Ig levels were markedly reduced in XBP1 CD19 mice (Fig. S1 C) . Fur thermore, these mice exhibited impaired Ig responses to the T cell-dependent antigen nitrophenol (NP)KLH upon pri mary or secondary stimulation (Fig. S2, A and B, respec tively). A similar defect was observed in mice immunized with the T cell-independent antigen NPficoll (Fig. S2 C) .
XBP1 upregulates the expression of UPRrelated target genes that function collectively in protein synthesis and se cretion. XBP1 targets include the ERassociated degradation protein EDEM, ERlocalized chaperones like ERlocalized Dnajb9 (ERdj4), the ER translocon component Sec61, and proteins, such as protein disulfide isomerase (PDI) , that aid disulfide bond formation (Todd et al., 2008) . Using B220 + splenocytes isolated from XBP1 CD19 and XBP1 +/+ mice, we next measured the expression of XBP1 target genes in these B cells after culture for 0-3 d in the presence or absence of 10 µg/ml LPS (Fig. S3 A) . As expected, quantitative PCR analysis demonstrated that, by day 3 of culture, there were significant increases in the expression of the aforementioned XBP1 target genes in XBP1 +/+ B cells. These same target genes were upregulated to a lesser degree or not at all in XBP1 CD19 B cells. In addition, XBP1 CD19 B cells did not demonstrate an appropriate upregulation of S, which nor mally allows for newly synthesized IgM to be secreted. Importantly, B cells from XBP1 CD19 and XBP1 +/+ mice showed no difference in their modest increase in expression of Ig heavy chain binding protein (BiP), another UPR related gene which is not directly downstream of XBP1.
XBP1 deletion did not affect B cell proliferation or viabil ity in response to LPS treatment. Both were comparable be tween XBP1 CD19 and XBP1 +/+ B cells as measured by exclusion of 7aminoactinomycin D (7AAD) and annexin V (Fig. S3 B) or by exclusion of trypan blue (Fig. S3 C) . In contrast, XBP1 deletion led to markedly reduced secretion of IgM by LPS stimulated XBP1 CD19 B cells (Fig. S3 D) . Collectively, these data demonstrate that XBP1 deletion leads to defects in the UPR that impair normal synthesis and secretion of immuno globulin without affecting B cell viability or proliferative prop erties. Importantly, these initial experiments in XBP1 CD19 mice recapitulated the known roles of XBP1 in PC development and function, as has been shown previously using XBP1/ RAG2 / lymphoid chimeric mice (Reimold et al., 2001) .
We next investigated the impact of XBP1 deficiency on the broader network of transcriptional regulators that direct PC differentiation (for review see Calame et al., 2003) . The transcription factors Bcl6 (B cell lymphoma 6) and paired box gene 5 (Pax5) repress B lymphocyte-induced maturation protein 1 (Blimp1) and IFN regulatory factor 4 (IRF4), re spectively, and promote B cell proliferation and the GC reac tion. On the contrary, Blimp1 and IRF4 normally arrest cell cycle progression and the GC reaction to promote and sus tain PC development . Furthermore, Blimp1 and IRF4 permit the expression of XBP1 (Shaffer previously that XBP1 expression is required for normal PC development and function as well (Reimold et al., 2001) . Chimeric mice demonstrated markedly reduced serum Ig levels and impaired Ig response to immunization. This defect was the result of a failure of cells to upregulate UPRrelated XBP1 target genes during terminal B cell differentiation Shaffer et al., 2004) . The requirement of XBP1 for PC differentiation raises the possibility that dis ruption of XBP1 activity may represent a potential therapeu tic target for the treatment of autoimmune diseases, such as systemic lupus erythematosus (SLE), in which autoantibodies may be directly pathogenic.
Little is known about the role of XBP1 in the develop ment and function of another important B cell population: memory B cells. These B cells have been exposed to antigen, undergo a germinal center (GC) reaction, and function to differentiate rapidly into antibodysecreting B cells after reexposure to cognate antigen (for review see McHeyzer Williams and McHeyzerWilliams, 2005) . They do not express CD138 (syndecan1), a cell surface glycoprotein which has traditionally been used a marker for Igsecreting PCs (Sanderson and Børset, 2002) . Memory B cells also function to replete the pool of longlived antibodysecreting PCs (for review see McHeyzerWilliams and McHeyzerWilliams, 2005) , which may represent a persistent source of autoantibodies (Neubert et al., 2008) .
The recent development of a XBP1 flox conditional KO (cKO) mouse (Hetz et al., 2008) has prompted us to explore further the function of XBP1 in terminal B cell development. CD19 expression is limited to B cells and occurs in pro-B cells and throughout the remaining stages of B cell develop ment (Zhou et al., 1991; Hardy and Hayakawa, 2001) . We therefore bred the XBP1 flox cKO mouse to a mouse express ing cre recombinase under the control of CD19 promoter to delete XBP1 selectively from B cells (Rickert et al., 1997 ). In the current series of experiments, we use XBP1 flox/flox CD19 cre/+ (XBP1 CD19 ) cKO mice first to confirm the func tional PC defects in XBP1/RAG2 / lymphoid chimeric mice (Reimold et al., 2001 ). In addition, we now report that XBP1 CD19 mice were protected from mouse lupus. We also show, unexpectedly, that the number of cells with the tradi tional B220 int CD138 + PC phenotype is normal in XBP1 CD19 mice as compared with XBP1 flox/flox CD19 +/+ (XBP1 +/+ ) controls. Finally, we report that XBP1 CD19 mice have normal populations of memory B cells, demonstrating that this alter native differentiation pathway for B cells is not dependent on the XBP1 branch of the UPR.
RESULTS AND DISCUSSION
Initial characterization of XBP1 CD19 cKO mice To determine the efficiency of XBP1 deletion in the B cells in XBP1 CD19 mice, splenocytes from these mice were isolated and separated into B220 + and B220  populations using mag netic beads coupled to an antiB220 mAb. Southern blotting demonstrated efficient and specific deletion of XBP1 in the B220 + (B cell) fraction (Fig. S1 A) . There were no differences
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When treated with bortezomib, these lupusprone mice lacked autoantibodies, were devoid of mature PCs, and were protected from mouse lupus. Proteasome inhibitors suppress ERassociated degradation pathways such that misfolded proteins accumulate in cells, cause ER stress, and induce the UPR (Obeng et al., 2006) . Chronic ER stress, however, causes cell cycle arrest and cellular apoptosis (Zinszner et al., 1998; Brewer and Diehl, 2000) . Proteasome inhibitors like Klein et al., 2006) . For Blimp1, this regulatory event is accomplished by Blimp1mediated repression of Pax5, which derepresses XBP1 to ensure an appropriate UPR in anticipation of Ig production and secretion (Shaffer et al., 2004) . Despite the failure to differentiate into Igsecreting PCs, LPSstimulated XBP1 CD19 B cells displayed a typical PC signature of these transcription factors: downregulation of Pax5 and upregulation of Blimp1 and IRF4 mRNAs. Inter estingly, Blimp1 and IRF4 were substantially overexpressed in LPSstimulated XBP1 CD19 B cells compared with XBP1 +/+ controls (Fig. S3 A) . These data suggest that XBP1 deletion did not alter the genetic program of PC development. Fur thermore, failure to upregulate Ig secretion in the absence of XBP1 appears to promote the PC developmental program, supporting the hypothesis that a mechanism of feedback inhi bition exists whereby XBP1 downregulates Blimp1 and IRF4 expression in LPSstimulated B cells (Hu et al., 2009 ).
Mice with XBP1-deficient B cells are protected from mouse lupus BALB/c mice develop anti-doublestranded DNA (dsDNA) autoantibodies and immune complex deposits in glomeruli when immunized with a DNA mimotope, the decapeptide DWEYSVWLSN on a polylysine backbone (MAPDWEYS; Putterman and Diamond, 1998) . Furthermore, when treated with LPS to disrupt the blood brain barrier, MAPDWEYSimmunized mice develop lesions in the hippocampus of the brain, a process which is attributable to excitatory cell death induced by stimulatory autoantibodies bound to neuronal Nmethyldaspartic acid (NMDA) receptors (Kowal et al., 2004) . AntiNMDA receptor autoantibodies have also been identified in the cerebrospinal fluid of humans with SLE, and this mouse system has been used as a model of human central nervous system lupus (DeGiorgio et al., 2001; Kowal et al., 2006) .
We next sought to use this mouse model of SLE to test whether XBP1 CD19 mice were capable of developing auto antibodies and associated pathological findings of mouse lupus. XBP1 CD19 and littermatched XBP1 +/+ mice were immu nized with MAPDWEYS three times over a 1mo period, as described in Materials and methods. Serum antipeptide and antidsDNA antibodies were readily detected in XBP1 +/+ control mice but were only weakly present in XBP1 CD19 mice (Fig. 1, A and B). These same mice were then treated with 3 mg/kg LPS and killed 4-7 d later for immunohisto chemistry (IHC) analysis of kidney and brain ( Fig. 1 C) . IHC revealed abundant IgG in glomeruli of five out of five control mice and in the hippocampus of two out of five controls, but none was present in any of the XBP1 CD19 mouse tissues. Thus, mice with B cells deficient in XBP1 were protected from autoantibody production and disease expression in this mouse model of SLE.
This observation is reminiscent of a recent compelling study in which two lupusprone mouse strains (NZB/W F1 and MRL/lpr) were treated with bortezomib, a selective inhibi tor of the 26S proteosome which is used therapeutically to treat human myeloma, a PC malignancy (Neubert et al., 2008) . arrest. This occurs before achieving normal PC morphology and functional activity because of a failure to upregulate XBP1dependent UPR target genes. CD138 is a member of the syndecan family of heparin sulfate proteoglycans and is comprised of a transmembrane core protein covalently bonded to heparin sulfate moieties (Sanderson and Yang, 2008) . CD138 also exists as part of the bone marrow stroma and in a soluble form that may be shed from cell membranes. Cell surface-bound CD138 impairs invasion of myeloma cells through collagen gels (Liebersbach and Sanderson, 1994) , facilitates cell-cell aggregation (Stanley et al., 1995) , and promotes myeloma adhesion to collagen in the extracel lular matrix (Ridley et al., 1993) . These functions have been hypothesized to explain the organ selectivity of myeloma bortezomib are toxic to myeloma cells, in part through targeting the activity of IRE1 Obeng et al., 2006) . These findings raise the intriguing notion that inhibi tion of XBP1 or the UPR in general may represent a poten tial therapeutic target in the treatment of autoantibodymediated diseases like SLE.
The developmental defect in XBP1-deficient PCs occurs after CD138 expression XBP1 CD19 mice allow us to explore further the developmen tal stage at which PC differentiation arrests. Complicating this analysis, however, is the observation that PCs down regulate many B cell surface markers such as B220, CD19, and CD20 (Hardy and Hayakawa, 2001 ). Traditionally, cell surface expression of CD138 by B cells has been viewed as a marker for antibodysecreting PCs (B220 int CD138 + cells; Sanderson and Børset, 2002) . Accordingly, we immunized XBP1 CD19 and XBP1 +/+ mice with NPKLH to measure the distribution of B220 and CD138 staining over time. Surpris ingly, even though XBP1 CD19 mice had markedly impaired Ig responses to immunization (Fig. S2) , both XBP1 CD19 and XBP1 +/+ mice had comparable numbers of B220 int CD138 + splenocytes (Fig. 2 A) . In XBP1 CD19 mice, these cells lacked the expanded ER and perinuclear cuff of Golgi found in normal PCs (Fig. 2 B) . This difference was quantifiable; B220 int CD138 + cells from XBP1 CD19 mice demonstrated less intensive staining by brefeldin A borondipyrromethane (BODIPY), which selectively binds to secretory ER and Golgi content (Fig. 2 C) (Hetz et al., 2008) . 5 d after NPKLH immunization, splenocytes from XBP1 CD19 and XBP1 +/+ mice were isolated and FACS sorted into B220 int CD138 + and B220 + CD138  cell populations, from which RNA was purified for quantitative PCR analy sis. In accord with what is known about PCs, B220 int CD138 + cells from XBP1 +/+ mice expressed much greater levels of the XBP1 target genes ERdj4, EDEM, PDI, and Sec61 as com pared with B220 + CD138  cells from the same mice (Fig. 3 ). There were also increased levels of BiP, S, Blimp1, and IRF4 and reduced levels of Pax5. These differences were also observed, but to a much lesser degree, in the two sorted XBP1 CD19 B cell populations. When comparing B220 int CD138 + cells from XBP1 CD19 and XBP1 +/+ mice, XBP1 target genes and S were reduced in expression in cKO cells, and levels of BiP and Pax5 were similar. Unlike what was observed in LPSstimulated B cells, however, levels of Blimp1 and IRF4 were not elevated in cells from XBP1 CD19 mice. This sup ports the hypothesis that there are multiple pathways of B cell differentiation depending on the specific exogenous stimulus. Indeed, in vitro LPSstimulated B cells behave differently than in vivo immunogenstimulated B cells, and this is likely caused, in part, by the absence of T helper cell activity as well as by the different activation pathways involved (for review see McHeyzerWilliams and McHeyzerWilliams, 2005) .
Collectively, our data show that XBP1 CD19 B cells can survive and differentiate to the developmental stage at which they express CD138, at which point they developmentally 
which is then followed by XBP1directed UPR transcrip tional events and largescale immunoglobulin secretion. This differs from our previously published results in which CD138 was not detected on the surface of XBP1deficient B cells 9 d after immunization with 2,4dinitrophenyl (DNP)albumin in XBP1/RAG2 / lymphoid chimeric mice (Reimold et al., 2001) . One limitation of the XBP1/RAG2 / lymphoid chi meric model, however, is that it cannot ascribe this difference solely to an intrinsic deficiency of XBP1 in B cells. With the recent discovery that XBP1 is important for the normal devel opment and function of dendritic cells (Iwakoshi et al., 2007) , one could conjecture that XBP1 function in non-B cell pop ulations might in part explain the reduced numbers of CD138 + cells in the chimeric mice. Thus, the XBP1 CD19 cKO system provides some refinement in our understanding of the rela tionship between XBP1 and CD138 expression.
Post-GC memory cells and preplasma memory cells are intact in mice with B cells that lack XBP1
Memory B cells make up the second major population of terminally differentiated B cells (for review see McHeyzer Williams and McHeyzerWilliams, 2005) . They are long lived antigenspecific cells that reside mainly in peripheral cells, and CD138 is being investigated as a potential thera peutic target in myeloma (Sanderson and Yang, 2008) .
The role of CD138 in normal PCs, however, is less well defined, although it may have similar bone marrow homing functions in PCs as in myeloma cells. CD138 is expressed on the cell surface of PCs and bone marrow-resident B cell precursors. It is not present on the surface of mature naive B cells in the bone marrow, circulation, or secondary lym phoid organs (Sanderson et al., 1989) . CD138 expression has been closely correlated with Ig secretion (Lalor et al., 1992) , and CD138 + plasmablasts have been previously described (AngelinDuclos et al., 2000) , but the existence of a nonIgsecreting CD138 + cell population has not been formally demonstrated until now. The converse has been seen, how ever, in that Blimp1deficient B cells do not express CD138 but can secrete small amounts of Ig (ShapiroShelef et al., 2003; Kallies et al., 2007) . However, this represents an earlier (initial) developmental stage of PC differentiation in that these cells are unable to attain the large secretory capabilities or phenotype of mature PCs (Kallies et al., 2007) . IRF4 deficient B cells also fail to express CD138 (Klein et al., 2006) .
Our findings therefore indicate that in developing PCs, Blimp1 and IRF4 expression precedes CD138 expression, cess. Neither Blimp1 nor IRF4 are required for the develop ment of postGC memory B cells (ShapiroShelef et al., 2003; Klein et al., 2006) . Blimp1deficient B cells, however, fail to differentiate into preplasma memory B cells (Shapiro Shelef et al., 2003) . Furthermore, IRF4deficient postGC B cells can expand upon reencounter with cognate antigen (a memory cell-driven response), but they fail to differentiate into PCs (Klein et al., 2006) . Thus, neither of these transcrip tion factors appears to be crucial for development of the memory B cell population de novo.
tissues, including in the lung, gut, and peripheral lymphoid organs. When reexposed to cognate antigen, memory B cells proliferate, and a subset differentiates into antibodysecreting PCs. Memory B cell subpopulations can be distinguished phenotypically as postGC B cells (B220 + CD138  ) or pre plasma memory B cells (B220  CD79b + CD138  ; for review see McHeyzerWilliams and McHeyzerWilliams, 2005) .
Little is known about the transcriptional programs that regulate B cell differentiation into memory cells, including whether there is any role for XBP1 or the UPR in this pro [PI, CD4, CD8, F4/80, GR1] neg IgD lo NP + CD138 + splenocytes of day-5 and day-14 immunized mice were sorted directly ex vivo into NP-specific Ig (IgM or IgG) revealing ELISPOT assays. Positives were scored manually under a dissection microscope. Each assay was done in triplicate from three separate animals (mean ± SEM; n = 3; unpaired Student's t test; *, P ≤ 0.05).
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are solely the result of a failure of formation of antibody secreting PCs and not of B cell memory itself.
Summary
Collectively, this analysis of B cells from XBP1 CD19 cKO mice expands our understanding of the crucial role of XBP1 in terminal B cell development as it pertains to PC develop ment, autoantibodymediated autoimmune disease, and memory cell development. Deletion of XBP1 leads to failed upregu lation of the UPR in developing PCs with subsequent defi ciencies in antibody responses to antigen. Interestingly, the experiments presented here identify and characterize a pre viously unrecognized population of antibody hyposecreting B220 int CD138 + B cells in XBP1 CD19 mice, demonstrating that XBP1mediated UPR events occur after the develop mental stage at which CD138 is expressed. Importantly, we establish that memory B cell populations are unaffected by XBP1 deficiency such that XBP1related activity can be situ ated independent of the memory B cell lineage commitment. Finally, XBP1 CD19 mice are protected from autoantibody mediated mouse lupus. This has therapeutic implications from a clinical perspective in that inhibition of XBP1 or the UPR in general potentially represents a therapeutic target in the treatment of SLE.
MATERIALS AND METHODS

Mice and immunization.
The creation of XBP1 flox mice harboring loxP sites in the first and second intron of the XBP1 gene has been described pre viously (Hetz et al., 2008; Kaser et al., 2008; Lee et al., 2008) . These mice were backcrossed 10 generations with BALB/c mice, which was the back ground strain for all experiments described in these studies. XBP1 flox/flox mice were bred to CD19 cre/+ BALB/c mice that express cre recombinase under the control of the CD19 promoter (The Jackson Laboratory; Rickert et al., 1997) . Two generations of breeding yielded XBP1 CD19 cKO mice and XBP1 +/+ control mice. All mice were born in Mendelian ratios and devel oped normally. Wildtype BALB/c mice were purchased from Taconic. Experimental protocols were approved by the Standing Committee on Ani mals at the Harvard Medical School and were designed with institutional and National Institutes of Health guidelines for the humane use of animals.
To measure serum antibody responses to immunization, 6-8wkold XBP1 CD19 and XBP1 +/+ mice were injected i.p. with 100 µg NPKLH (Bio search Technologies) emulsified in alum (Thermo Fisher Scientific) or 25 µg NPficoll (Biosearch Technologies). Blood was collected from mice via retro orbital bleed at the time of immunization and weekly for 2 wk. To measure secondary serum antibody responses, some mice that had received NPKLH were reimmunized with 100 µg NPKLH in alum 8 wk after primary immu nization, and additional blood samples were obtained at the time of reimmu nization and weekly for 2 wk. For NPspecific B cell studies, 8-14wkold mice were immunized subcutaneously with 400 µg NPKLH in Ribi adju vant (laboratory formulation based on Baldridge and Crane [1999] ).
B cell isolation and culture. Single cell suspensions of splenocytes were prepared from 6-8wkold mice, and erythrocytes were removed by os motic lysis with NH 4 Cl buffer (SigmaAldrich) as previously described . Splenic B cells were purified using B220 + magnetic bead selection (Miltenyi Biotech) and confirmed to have >90% purity by flow cytometry for cell surface CD19 expression. For some B cell prepara tions, Southern blotting was used to determine efficacy of XBP1 deletion in B220 + lymphocytes. The remaining B220 + splenocytes from XBP1 CD19 and XBP1 +/+ mice were cultured at 10 6 cells/ml for 0-3 d in the presence or ab sence of 10 µg/ml LPS (SigmaAldrich) in complete media containing
We have already demonstrated that secondary Ig re sponses are markedly blunted in XBP1 CD19 mice (Fig. S2) . Using a well established protocol to study memory B cells (ShapiroShelef et al., 2003) , we next sought to answer whether the defect in secondary memory responses in XBP1 CD19 mice is solely attributable to impaired antibody se cretion by PCs or whether there may also be independent deficiencies in memory B cell populations themselves. Mice were immunized with 400 µg NPKLH in Ribi adjuvant and splenocytes were isolated at day 5 or 14. Cells were stained with antibodies specific for CD4, CD8, F4/80 (a macrophage marker), GR1 (a granulocyte and monocyte marker), B220 (CD45R), CD138, IgD, GL7, CD38, and Ig  light chain. In addition, cells were stained with propidium iodide (PI) to determine viability and allophycocyanin (APC)conjugated NP to identify antigenspecific B cells. Viable postGC NP specific B cells were identified as those cells that excluded PI, were [CD4, CD8, F4/80, GR1] neg , and demonstrated a NP + IgD lo phenotype. The expansion of these cells after im munization was comparable between XBP1 CD19 and XBP1 +/+ mice (Fig. 4 A) .
These NPspecific B cells were further assayed for ex pression of B220 and CD138 to identify B220 + CD138  postGC memory cells, B220 lo CD79b + CD138  preplasma memory cells, and B220 int CD138 + cells with a PC pheno type (Fig. 4 B) . At day 5 after immunization, there were no differences in the relative or absolute numbers of the subpop ulations between XBP1 CD19 and XBP1 +/+ mice. At day 14, there were some differences in the relative numbers of these cells, but the absolute numbers were not significantly differ ent because the number of splenocytes and absolute number of NPspecific cells were up to twofold greater in XBP1 CD19 mice. There were no differences in the total number of antigen specific GC versus postGC events at day 14 as measured by CD138 neg GL7 hi CD38 lo GC B cells versus CD138 neg GL7 lo CD38 hi postGC B cells (Fig. S4 A) . There were also no differences between XBP1 CD19 and XBP1 +/+ mice when assayed for the repertoire of  light chain expression by anti genspecific B cells (Fig. S4 B) . ELISPOT was used to mea sure the ability of FACSpurified B220 int CD138 + cells to secrete IgM and IgG. At days 5 and 14, the number of NP specific IgGsecreting B cells was significantly reduced in XBP1 CD19 mice as compared with controls (Fig. 4 C) . Similar results were obtained for NPspecific IgMsecreting cells at day 5 but not at day 14. These assays reinforce the notion that XBP1 CD19 B cells are able to differentiate into B220 int CD138 + cells but lack the normal capacity for Ig secretion.
Thus, XBP1 CD19 B cells are capable of differentiating nor mally into postGC or preplasma memory B cell populations. These observations again place XBP1mediated events downstream of Blimp1, which is crucial for the development of preplasma memory B cell (ShapiroShelef et al., 2003) . These data also show for the first time that the XBP1driven branch of the UPR is unnecessary for the development of memory B cells themselves. Thus, the defects in Ig produc tion during secondary antigen challenge in XBP1 CD19 mice RNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). Quantitative realtime PCR reactions using SYBR green fluo rescent reagent were run in an Mx3005P system (Agilent Technologies) and analyzed as previously described (Iwakoshi et al., 2007) . Primer sequences are listed in Table S1 .
Mouse lupus. Using an established model of mouse lupus (Kowal et al., 2004) , 6-8wkold XBP1 CD19 and XBP1 +/+ mice were immunized i.p. with 100 µg MAPDWEYS emulsified in CFA (SigmaAldrich). Booster immu nizations with 100 µg MAPDWEYS in IFA (SigmaAldrich) were given on days 14 and 28. Serum was obtained from these mice on day 35 and tested for antipeptide and antidsDNA antibodies as previously described (Kowal et al., 2004) . There were five mice per group. To disrupt the blood brain barrier in the hippocampus, mice were given i.p. injections of 3 mg/kg LPS (Escherichia coli, 055:B5; SigmaAldrich) on days 52 and 54. Mice were then killed 4-7 d after LPS treatment to analyze tissues for histological evidence of mouse SLE. After cardiac perfusion, brains and kidneys were isolated and tissues were immunostained for IgG as previously described (Putterman and Diamond, 1998; Kowal et al., 2004) .
Online supplemental material. Table S1 lists primer sequences used for quantitative realtime PCR. Fig. S1 shows XBP1 deletion and basal immuno globulin production in XBP1 CD19 mice. Fig. S2 shows immunoglobulin production in immunized XBP1 CD19 mice. Fig. S3 shows in vitro analysis of XBP1deficient B cells. Fig. S4 shows additional characterization of memory cells in XBP1 CD19 mice. Online supplemental material is available at http:// www.jem.org/cgi/content/full/jem.20090738/DC1. RPMI 1640 supplemented with 10% FBS (Hyclone Laboratories), 2 mM glutamine, 50 U/ml penicillin, 50 µg/ml streptomycin, 100 mM Hepes, nonessential amino acids, 1 mM sodium pyruvate, and 50 µM mercapto ethanol. Cells were harvested on days 0-3 of culture for RNA extraction and quantitative PCR analysis. In addition, on day 3 of culture, supernatants were tested by enzymelinked immunosorption assay ELISA to quantify IgM production, cells were harvested for viability assay by annexin V and 7AAD staining, and cell counts by exclusion of trypan blue.
Flow cytometry and cell sorting. Splenocytes were prepared as described in the previous section. Non-NPspecific flow cytometry and FACS were performed using antibodies specific for mouse IgM, IgD, B220, CD19, or CD138 (BD) as previously described (Iwakoshi et al., 2007) . To measure cell viability, cells were stained with PEconjugated annexin V and 7AAD ac cording to manufacturer instructions (BD). Viable cells exclude both stains. To measure the cellular content of ER and Golgi organelles, cells were stained with Brefeldin A-BODIPY (Invitrogen) at 0.2 µg/ml at 37°C for 40 min before flow cytometric analysis as previously described (Hetz et al., 2008) . Cytospin samples of FACSsorted B220 int CD138 + cells were pre pared from XBP1 CD19 and XBP1 +/+ mice and stained with modified Wright Giemsa stain according to the manufacturer's instructions (SigmaAldrich).
For NPspecific B cell studies, spleens were harvested at day 5 or 14 after immunization and single cell suspensions were prepared as previously de scribed (McHeyzerWilliams et al., 2000) . Cell suspensions were labeled for flow cytometry at 2 × 10 8 cells/ml on ice for 45 min with the following flu orophorelabeled mAbs or Ag: FITC11.26 (antiIgD; McHeyzerWilliams laboratory), FITCGL7 (BD), PE281.2 (antiCD138/syndecan1; BD), PE90 (antiCD38; BD), Cy5PEH129.19 (antiCD4; BD), Cy5PE536.7 (antiCD8; BioLegend), Cy5PEF4/80 (eBioscience), Cy5PERB68C5 (antiLy6G/GR1), Cy7PE6B2 (antiCD45R/B220), APCNP (4hydroxy 5iodo3nitrophenyl; McHeyzerWilliams laboratory), and biotinHM79b (antiCD79b/Ig; McHeyzerWilliams laboratory). StreptavidinCy7APC (BD) was used as a secondstep revealing reagent. Cells were washed and re suspended in 2 µg/ml PI for dead cell exclusion in PBS with 5% FCS for analysis. Samples were analyzed using a FACS Vantage SE (BD) and data an alyzed using Flow Jo software (Tree Star, Inc.). Profiles are presented as 5% probability contours with outliers.
ELISA and ELISPOT assays. ELISA was used to quantify IgM levels in cell culture supernatants and levels of IgM, IgG1, IgG2a, IgG2b, IgG3, and IgA in the serum of XBP1 CD19 and XBP1 +/+ mice as previously described (Reimold et al., 2001) . To measure the relative amounts of NPspecific serum antibodies in mice immunized with NPKLH or NPficoll, plates were coated with 25 µg/ml NP(25)BSA (Biosearch Technology) overnight at 4°C. To standardize and quantify relative amounts of NPspecific IgG re sponses, all experimental samples were compared with a standardized dilu tion of pooled serum obtained from XBP1 +/+ mice immunized with NPKLH or NPficoll and bled on day 14. NPspecific ELISA was other wise performed as previously described (Reimold et al., 2001) . Serum anti peptide and antidsDNA antibodies were tested by ELISA as previously described (Kowal et al., 2004) .
ELISPOT for detection of NPspecific Ig was performed as described previously (McHeyzerWilliams et al., 1993; McHeyzerWilliams et al., 2000) . 96well multiscreen membrane filtration plates (Millipore) were coated with 25 µg/ml NPBSA overnight at 4°C. The wells were washed and incubated with RPMI 1640 and 5% FCS, and 25-50 [PI, CD4, CD8, F4/80, GR1] neg IgD lo NP + CD138 + cells were sorted directly into each well and incubated for >18 h at 37°C in 5% CO 2 . The wells were washed before the addition of horseradish peroxidase goat anti-mouse IgM or IgG (South ernBiotech) for 4 h and developed using 3amino9ethylcarbazole (Sigma Aldrich). Wells were manually scored by a person blinded to the test conditions using a dissection microscope. Each assay was done in triplicate wells from three separate animals.
Quantitative PCR. Total RNA was isolated from cells using TRIzol re agent (Invitrogen), and complementary DNA (cDNA) was synthesized from
